Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

EVMN vs OMER: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OMER Captures Overall Composite Edge (54.1 HOLD vs 30.0 SELL), While EVMN Leads 3–2 on Growth & Valuation Pillars

OMER Overall Winner 6-Pillar Tally: EVMN 3 – 2 OMER (1 Tie) Matrix Metrics: EVMN 2 – 8 OMER

As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Evommune, Inc. (EVMN) on higher Unified Composite conviction (54.1/100 HOLD vs. 30.0/100 SELL) after splitting the core matrix 8–2 (led by Valuation Multiples, Growth & Scale), while EVMN wins 3–2 across the 6-pillar growth and valuation breakdown. EVMN trades at $7.10 (N/M Forward P/E, 0.0% operating margin) versus OMER at $16.68 (73.0x Forward P/E, -189.5% operating margin).

  • Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. EVMN 30.0/100 SELL) and 1.82β · 54% Vol risk profile, whereas EVMN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About EVMN vs OMER
EVMN US Equity
Evommune, Inc.
Pharmaceutical Preparations
$7.10
-6.95% 1D
Market Cap $315.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.05β · 118% Vol
Unified Composite Score
30.0 / 100 SELL
Tech 50.0 Fund 35.0 Flow 69.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.2 · SMA20: $6.45 · SMA50: $7.47
OMER NASDAQ Head-to-Head Winner
Omeros Corporation
Pharmaceutical Preparations
$16.68
-4.63% 1D
Market Cap $1.3B
TTM Revenue $27M
Forward P/E 73.0x
Beta / 30D Vol 1.82β · 54% Vol
Unified Composite Score
54.1 / 100 HOLD
Tech 44.0 Fund 55.0 Flow 74.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 46.9 · SMA20: $17.47 · SMA50: $18.23

6-Pillar Scorecard Institutional Category Breakdown (EVMN 3 – 2 OMER)

Columns: Metric · EVMN · OMER
1. Valuation Multiples OMER
Forward P/E N/M 73.0x
Trailing P/E N/M 14.3x
PEG Ratio N/M 0.81x
EV / Revenue N/M 50.1x
2. Growth & Scale OMER
Revenue Growth (YoY) +0.0% +14.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $27M
Market Cap $315.5M $1.3B
3. Profitability & Quality EVMN
Gross Margin N/A 38.3%
Operating Margin 0.0% -189.5%
Net Profit Margin 0.0% 324.9%
Return on Equity (ROE) -69.5% -576.3%
4. Balance Sheet & Cash Flow EVMN
Cash Generation (TTM) -$75M -$49M
Cash Flow Margin N/A N/A
Net Cash / Leverage $52M Net Cash $97M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning EVMN
Options Structure Phase SURGE CONSOLIDATION
Current IV / %ile 209.0% (53rd %ile) 85.5% (28th %ile)
Put/Call OI Skew N/A 0.09x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: EVMN (2) vs OMER (8)
Institutional Metric EVMN OMER Criterion Row Edge
Market Capitalization
Scale
$315.5M $1.3B Larger Scale OMER
Trailing P/E Ratio
Valuation
N/M 14.3x Lower Multiple OMER
Forward P/E Ratio
Valuation
N/M 73.0x Lower Multiple OMER
Revenue Growth (YoY)
Growth
+0.0% +14.9% Higher Growth OMER
Operating Margin (TTM)
Profitability
0.0% -189.5% Higher Margin EVMN
Net Profit Margin
Profitability
0.0% 324.9% Higher Margin OMER
Return on Equity (ROE)
Capital Efficiency
-69.5% -576.3% Higher ROE EVMN
52-Week Range Position
Momentum
8% ($5–$33) 70% ($6–$21) Stronger Trend OMER
Beta / 30D Volatility
Risk Regime
1.05β · 118% Vol 1.82β · 54% Vol Lower Realized Risk OMER
Unified Institutional Score
Composite Signal
30.0 / 100 (SELL) 54.1 / 100 (HOLD) Higher Composite OMER
Trailing 12M Revenue (USD)
Operating Scale
N/A $27M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 38.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 0.81x PEG · 50.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$75M ($52M Net Cash) -$49M ($97M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon EVMN +34.37 pp
EVMN: +37.33% · OMER: +2.96%
3M Horizon OMER +47.1 pp
EVMN: -50.07% · OMER: -2.97%
6M Horizon OMER +110.13 pp
EVMN: -67.57% · OMER: +42.56%
1Y Horizon OMER +226.64 pp
EVMN: -61.03% · OMER: +165.61%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period EVMN Revenue OMER Revenue EVMN Op. Margin OMER Op. Margin Margin Leader
FY2015 N/A $10M N/A -527.3% OMER
FY2016 N/A $40M N/A -130.4% OMER
FY2017 N/A $60M N/A -67.7% OMER
FY2018 N/A $30M N/A -375.7% OMER
FY2019 N/A $110M N/A -130.6% OMER
FY2020 N/A $70M N/A -212.6% OMER
FY2024 $10M N/A -1000.2% N/A EVMN
FY2025 $10M N/A -623.6% N/A EVMN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
EVMN SURGE
5d in phase · OBV ACCUMULATION
Current IV 209.0%
IV Percentile 53rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact EVMN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
OMER CONSOLIDATION
39d in phase · OBV DISTRIBUTION
Current IV 85.5%
IV Percentile 28th %ile
Put/Call OI Skew 0.09x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact OMER Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
EVMN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $315.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
OMER Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.3B market capitalization and -189.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ EVMN vs OMER Key Questions & Quantitative Answers

As of Nov 16, 2026, Omeros Corporation (OMER) captures the overall head-to-head institutional edge over Evommune, Inc. (EVMN) on higher Unified Composite conviction (54.1/100 HOLD vs. 30.0/100 SELL) after splitting the core matrix 8–2 (led by Valuation Multiples, Growth & Scale), while EVMN wins 3–2 across the 6-pillar growth and valuation breakdown. EVMN trades at $7.10 (N/M Forward P/E, 0.0% operating margin) versus OMER at $16.68 (73.0x Forward P/E, -189.5% operating margin). Growth vs. Quality Trade-Off: OMER earns the overall head-to-head edge with a stronger Unified Composite Score (54.1/100 HOLD vs. EVMN 30.0/100 SELL) and 1.82β · 54% Vol risk profile, whereas EVMN leads top-line expansion (+0.0% YoY revenue growth, N/M PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

OMER leads the Growth & Scale pillar: EVMN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with OMER at +14.9% YoY revenue growth and +0.0% YoY earnings growth on $27M TTM revenue (38.3% gross margin, -189.5% operating margin). Across the 8-period historical trajectory (FY2015 to FY2025), EVMN cumulative revenue shifted +0.0% while OMER shifted +600.0%. In operating R&D and SG&A reinvestment, EVMN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for OMER.

OMER screens cheaper on headline valuation multiples. EVMN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas OMER trades at 73.0x Forward P/E, 14.3x Trailing P/E, 0.81x PEG, and 50.1x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against EVMN (-69.5% ROE) versus OMER (-576.3% ROE) capital efficiency.

In options market volatility and institutional positioning, EVMN carries 209.0% implied volatility (53rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (1.05β · 118% Vol realized risk). By comparison, OMER carries 85.5% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.09x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.82β · 54% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.